Here, we suggest that HSP90 inhibition could alter the endothelial response by stimulating VEGFR2 proteolysis, thus further validating the use of geldanamycin (and other HSP90 inhibitors) as agents to block tumor angiogenesis and highlighting differential pharmacological effects in vascular physiology versus tumor progression. The gene discussed is HSP90AB1; the disease is neoplasm.